Form 4: Assertio Holdings Acquired by Zydus in $23.50 Cash Deal

EVP and CFO Ajay Patel reports the disposition of all equity holdings following the completion of Assertio Holdings' acquisition by Zydus Worldwide DMCC.

Summary

• Assertio Holdings, Inc. (ASRT) has been acquired by Zydus Worldwide DMCC.
• The acquisition was completed via a tender offer and subsequent merger effective June 16, 2026.
• Shareholders received $23.50 per share in cash for their common stock.
• Reporting person Ajay Patel (EVP and CFO) disposed of 15,942 shares of common stock and various derivative securities as part of the merger agreement.
• All outstanding restricted stock units (RSUs) and stock options were cancelled and converted into cash payments based on the $23.50 offer price.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing documenting the final exit of an executive following a completed corporate acquisition.

Positives

• Shareholders received a definitive cash exit at $23.50 per share.
• Unvested RSUs were accelerated and vested immediately prior to the merger.
• In-the-money stock options were cashed out based on the spread between the offer price and the exercise price.

Negatives

• Stock options with exercise prices equal to or greater than the $23.50 offer price were cancelled without any cash payment.
• The company ceases to be an independent publicly traded entity.

Risks

• The company is now a wholly owned subsidiary of Zydus, eliminating public market exposure for investors.

Future Outlook

The company has been acquired and is now a wholly owned subsidiary of Zydus Worldwide DMCC; no further independent public guidance is provided.

Management Comments

• The filing confirms the disposition of securities pursuant to the Agreement and Plan of Merger dated May 13, 2026.

Industry Context

StockSavvy.ai notes that this acquisition represents a consolidation trend in the pharmaceutical sector, where larger entities like Zydus are absorbing mid-cap firms to expand their product portfolios and market reach.

Comparison to Industry Standards

• The all-cash acquisition structure is standard for pharmaceutical M&A transactions of this size.
• The treatment of unvested equity and in-the-money options aligns with typical change-in-control provisions found in executive compensation agreements.

Legal Proceedings

• The transaction was executed pursuant to a formal Agreement and Plan of Merger.

Stakeholder Impact

• Shareholders have been cashed out at the agreed offer price.
• Employees and management are subject to the integration plans of the new parent company, Zydus.

Next Steps

• Delisting of Assertio Holdings, Inc. common stock from public exchanges.

Key Dates

Keywords

ASRT, Assertio Holdings, Zydus, Merger, Acquisition, Form 4, Insider Transaction